Annual Inventory Report. For all NSF-owned equipment and real property having an original acquisition cost of $5,000 or more, the awardee must submit an annual inventory report to the NSF Property Administrator, Division of Administrative Services (DAS). The report must include all NSF owned equipment and real property purchased or constructed, including land and buildings, under one or more NSF awards or acquired by screening excess through the General Services Administration (GSA); and specify the award number, the type of equipment or property, serial number, acquisition price, acquisition date, current book value, and condition of the NSF owned equipment and real property. The report also should include a description of Construction-in-Progress (CIP) and Work-in- Progress (WIP) items and construction costs incurred to date. CIP is defined as real property that is in the process of being manufactured or fabricated but is not yet complete. WIP is defined as equipment that is in the process of being manufactured or fabricated but is not yet complete. CIP and WIP consist of the costs of direct materials, direct labor, direct purchased services and indirect costs, including general and administrative and overhead costs. Costs coded as such should not be depreciated. The inventory report should be submitted electronically to xxxxxx@xxx.xxx with a copy to the cognizant NSF Grants and Agreements Officer and must be received no later than August 15 each year.
Annual Inventory Report. Within [***] after the end of each Contract Year, commencing with the Quarter in which the First Commercial Sale of the Product in the Kiniksa Field in the Territory occurs, Kiniksa shall deliver electronically to Regeneron a written inventory report (the “Annual Inventory Report”) reconciling beginning and ending inventory and including (i) the number of units of Product distributed, but not sold (such as samples, donations, and write-offs) in the Territory during such Contract Year, (ii) the number of units of Product for the Territory that are lost, destroyed, expired, or become obsolete or spoiled during such Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. Contract Year, and (iii) the number of units of Product sold in the Territory during such Contract Year. To the extent reasonably practicable, each Annual Inventory Report shall provide such information broken out by lot numbers, dosage form and unit size, for units of Product contained in such report.
